Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Medicus Pharma Ltd. has submitted an Orphan Drug Designation application to the FDA for SkinJect®, a localized treatment for basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic disorder causing frequent skin cancers. The move targets a high unmet medical need with no approved therapies, aiming to offer a repeatable, non-surgical o…